Clinical Trial

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-02; most recent amendment 2026-05-26.
Status change: Active, Not Recruiting → Completed 2026-05-26
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-08-11
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-07-03
Trial Details
NCT Number NCT07011797
Lead Sponsor Corxel Pharmaceuticals
Conditions Obesity
Enrollment 250 participants
Start Date 2025-06-17
Primary Completion 2026-03-23 (estimated)
Study Completion 2026-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-28